Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

S Ikematsu1,2, A Nakagawara3, Y Nakamura3, S Sakuma4, K Wakai5, T Muramatsu1 and K Kadomatsu*,1

1Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showaku, Nagoya 466-8550, Japan; 2Pharmaceuticals Development Department, Meiji Dainies Co., Odawara 250-0862, Japan; 3Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan; 4Cell Signals Inc., Tokyo 101-0035, Japan; 5Department of Preventive Medicine/Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

Midkine (MK) is a heparin-binding growth factor that was originally discovered as the product of a retinoic acid-responsive gene during the differentiation of embryonal carcinoma cells (Kadomatsu et al., 1988; Tomomura et al., 1990; Muramatsu, 2002). The MK family consists of only two members, namely MK and pleiotrophin (PTN; also called HB-GAM), and is distinct from other heparin-binding growth factor families (Kurtz et al., 1995; Rauvala et al., 2000; Deuel et al., 2002; Muramatsu, 2002). Regarding the biological roles of MK, at least three important issues should be pointed out. First, a pivotal role of MK in the migration of inflammatory cells has been revealed by studies involving MK knockout mice; MK-deficient mice are more resistant to vascular restenosis and nephritis induced by reperfusion (Horiba et al., 2000; Sato et al., 2001). Second, MK exhibits neuroprotective activity (Michikawa et al., 1993; Unoki et al., 1994; Owada et al., 1999), and enhances neurite extension (Muramatsu et al., 1993). Induction of MK expression has been detected in reactive astrocytes in ischaemic lesions in human and animal brains (Wang et al., 1998; Wada et al., 2002). MK is deposited at senile plaques and neurofibrillary tangles in Alzheimer’s patients (Yasuura et al., 1993). MK binds to Aβ and inhibits its cytotoxicity (Yu et al., 1998). Third, MK is involved in carcinogenesis. Its expression is induced as early as at the precancerous stages of human colorectal and prostate carcinomas (Konishi et al., 1999; Ye et al., 1999), increases with the stages of human carcinomas, and is significantly linked to the prognosis (O’Brien et al., 1996; Mishima et al., 1997). MK transforms NIH3T3 cells (Kadomatsu et al., 1997), enhances fibrinolysis (Kojima et al., 1995), and promotes cell growth (Muramatsu and Muramatsu, 1991; Muramatsu et al., 1993; Takei et al., 2001), cell survival (Qi et al., 2000), cell migration (Takada et al., 1997; Maeda et al., 1999; Horiba et al., 2000; Qi et al., 2001), and angiogenesis (Choudhuri et al., 1997). MK antisense oligodeoxynucleotide suppresses tumour progression in nude mice (Takei et al., 2001, 2002).

The neuroblastoma is the most common solid malignant tumour in children. However, the molecular mechanisms underlying its pathogenesis and progression remain unclear, although several molecules, such as MYCN, TrkA, and TrkB, that are linked to the prognosis have been revealed (Brodeur et al., 1984; Nakagawara et al., 1995). This is one of the reasons why satisfactorily efficient therapies have not been established yet. A possible approach regarding such therapies is to seek molecular targets in neuroblastomas. We previously reported that MK mRNA expression is elevated in neuroblastoma specimens at all stages (Nakagawara et al., 1995). Interestingly, the other MK family member, PTN, is expressed at high levels in favourable neuroblastomas (Nakagawara et al., 1995). As MK is a secretory

Keywords: growth factor; midkine; molecular target; neuroblastoma; tumour marker

The heparin-binding growth factor midkine (MK) is the product of a retinoic acid-responsive gene, and is implicated in neuronal survival and differentiation, and carcinogenesis. We previously reported that MK mRNA expression is elevated in neuroblastoma specimens at all stages, whereas pleiotrophin, the other member of the MK family, is expressed at high levels in favourable neuroblastomas. As MK is a secretory protein, it can be detected in the blood. Here, we show a significant correlation of the plasma MK level with prognostic factors of neuroblastomas. The plasma MK level was determined in 220 patients with neuroblastomas, and compared with that in children without malignant tumors (n = 17, <500 pg ml−1). The plasma MK level became significantly elevated with advancing stages (stage 1: 445 pg ml−1 (median), n = 73; stage 2: 589, n = 39; stage 3: 864, n = 40; stage 4: 1445, n = 56; and stage 4S: 2439, n = 12). More importantly, a higher MK level was strongly correlated with poor prognostic factors: over 1 year of age (P = 0.0299), MYCN amplification (P < 0.0001), low TrkA expression (P = 0.0005), nonmass screening, sporadic neuroblastomas (P < 0.0001), and diploidy/tetraploidy (P = 0.0007). Thus, these results demonstrate that the plasma MK level is a good marker for evaluating the progression of neuroblastomas. Moreover, considering the ability of antisense MK oligodeoxynucleotide to suppress tumour growth of colorectal carcinoma cells in nude mice, as recently reported, the present study suggests that MK is a possible candidate molecular target for therapy for neuroblastomas.

British Journal of Cancer (2003) 88, 1522–1526. doi:10.1038/sj.bjc.6600938 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: growth factor; midkine; molecular target; neuroblastoma; tumour marker

Received 27 November 2002; accepted 25 February 2003
protein, the blood MK level could be a strong tool for monitoring the status of neuroblastomas. This paper demonstrates that an elevated plasma level of MK is indeed significantly correlated with poor prognostic factors. Our results also indicate that MK could be a candidate molecular target for therapy for neuroblastomas.

MATERIALS AND METHODS

Enzyme-linked immunoassay for human MK

An enzyme-linked immunoassay (EIA) for human MK was performed as described previously (Ikematsu et al, 2000). Briefly, human MK was produced using Pichia pastoris GS115 by transfection with a human MK expression vector, which was constructed into pHIL-D4 (Invitrogen, Carlsbad, California, USA). This yeast-produced human MK was used to immunise rabbits and chickens to raise antibodies. The rabbit anti-human MK antibody (50 μl of 5.5 μg ml⁻¹ in 50 ml Tris HCl (pH 8.2), 0.15 μl NaCl, 0.1% NaN₃) was coated onto the wells of microtitre plates (Polyorb plates, Nunc, Rochester, New York, USA) for 20 h at room temperature. After washing with 0.05% Tween 20 in PBS, the wells were blocked with 300 μl of 0.1% casein, 0.01% Microcide I (aMReSCO) in PBS for 20 h at 37°C. Plasma samples (10 μl each) were mixed with 100 μl of 50 μl Tris HCl (pH 8.4), 0.5 μl KCl, 0.1% casein, 0.5% BSA, 0.01% Microcide I, and 0.1 μg ml⁻¹ peroxidase-labelled chicken anti-human MK antibody. Aliquots of 50 μl of this mixture were added to wells prepared as described above, and further subjected to chromogenic detection at OD 450 using tetramethylbenzidine as the substrate. This EIA system shows linearity from 0 to 4 ng ml⁻¹ of MK, and there is no crossreaction with PTN (Ikematsu et al, 2000).

Plasma samples

Plasma samples were obtained from blood collected from outcome patients without malignant tumours (n = 17) and neuroblastoma patients (n = 220). The information is summarised in Table 1.

| Table 1 Blood samples | n |
|-----------------------|---|
| No malignant tumours  | 17|
| < 1 year              | 11|
| > 1 year              | 6 |
| Neuroblastomas        | 220|
| Stage 1               | 73 |
| Stage 2               | 39 |
| Stage 3               | 40 |
| Stage 4               | 56 |
| Stage 4S              | 12 |
| MYCN amplification +  | 176|
| MYCN amplification −  | 21 |
| High TrkA expression  | 157|
| Low TrkA expression   | 53 |
| Mass screening        | 122|
| Sporadic              | 82 |
| Hyperdiploidypentaploidy | 91 |
| Diploidy/tetraploidy | 119|
| < 1 year              | 154|
| > 1 year              | 52 |

Sum from each group number does not necessarily match the total number, because some information is missing for some individuals.

RESULTS

The plasma MK level increases with advancing stages

Plasma samples were collected from children without malignant tumours and neuroblastoma patients. The information on individuals and neuroblastomas is summarised in Table 1. Plasma from individuals without malignant tumours showed low levels of MK (116–483 pg ml⁻¹; median, 205) (Figure 1). These values are consistent with the data for sera from healthy adults (median, 154 pg ml⁻¹; cutoff value, 500 pg ml⁻¹) (Ikematsu et al, 2000). The EIA employed in the present study showed no difference between serum and plasma (data not shown). These results indicate that the plasma level of MK does not change with age, and that the cutoff value can be set as 500 pg ml⁻¹ for children.

The plasma MK level increased with advancing neuroblastoma stages. The median values were 445, 589, 864, 1445, and 2439 pg ml⁻¹ for stages 1, 2, 3, 4, and 4S, respectively (Figure 1). The percentages of patients showing MK levels of more than the cutoff value were 38.4, 59.0, 70.0, 83.9, and 91.7% for stages 1, 2, 3, 4, and 4S, respectively (Figure 1). The statistical significance is summarised in Table 2. Although stage 4S is included in the favourable group of neuroblastomas along with stages 1 and 2, the MK level was the highest at stage 4S among the stages. This may be interpreted as indicating that one of the parameters influencing the plasma MK level is the tumour volume.

An elevated plasma MK level is correlated with poor prognostic factors of neuroblastomas

The neuroblastoma is one of the best studied tumours. Several factors have been determined to be significantly linked to the prognosis. Cases with amplified MYCN show a poor prognosis (Brodeur et al, 1984). Low-level expression of the NGF receptor Trk A is linked to a poor prognosis (Nakagawara et al, 1993). Sporadic neuroblastomas show a worse outcome as compared with neuroblastomas detected by mass screening that is currently being carried out in Japan (Sawada, 1986). Neuroblastomas with diploidy or tetraploidy show a worse prognosis than those with hyperdiploidy or pentaploidy (Look et al, 1984). In addition, the outcome in patients of older than 1 year is worse compared with in patients of younger than 1 year (Fortner et al, 1968). All these prognostic factors were significantly correlated with a plasma MK level (Figure 2 and Table 3). A higher level of MK was correlated with MYCN amplification (P < 0.0001), low expression of TrkA (P = 0.0005), sporadic neuroblastomas (P < 0.0001), diploidy/tetraploidy (P = 0.0007), and older age (P = 0.0299).

DISCUSSION

This study demonstrated that the plasma MK level is significantly correlated with prognostic factors of human neuroblastomas. The only exception was that the plasma MK level was the highest at stage 4S among the stages, although stage 4S belongs to the favourable group of neuroblastomas. Stage 4S is a special type of stage 4. Tumours at stage 4S show spontaneous regression (Evans et al, 1976). Before spontaneous regression, stage 4S exhibits large tumours and metastasis to the liver, bone marrow, and skin.
The plasma MK level becomes elevated with advancing neuroblastoma stages. The plasma MK level in children without malignant tumours was 205 pg ml$^{-1}$ (median, $n=17$). Those at stages 1, 2, 3, 4, and 4S were 445 ($n=73$), 589 ($n=39$), 864 ($n=40$), 1445 ($n=50$), and 2439 ($n=12$), respectively. The percentage of cases showing more than the cutoff value (500 pg ml$^{-1}$) is shown in parentheses beneath each stage. The plasma MK level is significantly elevated at all neuroblastoma stages compared with the normal level. Statistical analysis is summarised in Table 2.

**Table 2**  Statistical analysis as to stages

| Stage   | Normal | Stage 1 | Stage 2 | Stage 3 | Stage 4 |
|---------|--------|---------|---------|---------|---------|
| 1       | <0.0001| 0.5     | <0.001  | <0.001  | <0.001  |
| 2       | <0.0001| 0.039   | 0.5     | <0.001  | 0.5     |
| 3       | <0.001 | <0.001  | 0.001   | 0.067   | 0.5     |
| 4       | 0.003  | 0.001   | 0.067   | 0.5     | 0.5     |
| 4S      | 0.001  | 0.001   | 0.067   | 0.5     | 0.5     |

The difference in serum MK level between the six groups was statistically significant ($P<0.0001$, by the Kruskal–Wallis test). $P$-values in this table for differences between the two groups were derived from the Mann–Whitney U-test with Bonferroni’s correction.

Previously reported that MK mRNA expression in tumour specimens is very high at all human neuroblastoma stages, including stage 4S, as compared with that in benign tumours, that is, ganglioneuromas (Nakagawara et al, 1995). The present data for plasma MK are, therefore, consistent with our previous data for mRNA expression in tumours. Taken together, the results for stage 4S suggest that the tumour volume is one of the factors that influence the plasma MK level. However, the tumour volume may not be the only factor that controls the plasma MK level, because we detected many cases that showed a high MK level even at stage 1 (Figure 1). In favourable neuroblastomas, for example, no MYCN amplification was discovered by mass screening, and we often observed high MK plasma levels. It should be noted that, even in favourable neuroblastomas, many cases exhibit poor clinical courses. We can expect that such cases can be evaluated and managed by means of monitoring the plasma level of MK. The importance of the present study is that it provided a chance to follow up prognosis of the patients with several parameters, including the plasma MK level. This perspective study is currently being carried out by our group, which will reveal the biological and clinical significance of an elevated plasma level of MK.

The present results also indicated that MK could be a candidate molecular target for therapy for neuroblastomas, because an elevated plasma MK level is linked with a poor prognosis. Cancer-related activities of MK have been reported by many laboratories. These activities include transforming, migrating, fibrinolytic, mitogenic, antiapoptotic, and angiogenic ones (Kojima et al, 1995; Choudhuri et al, 1997; Kadomatsu et al, 1997; Qi et al, 2000, 2001). Furthermore, we recently succeeded in suppressing tumour growth by using antisense MK oligodeoxyribonucleotide (Takei et al, 2001, 2002). Thus, ablation of MK production or disruption of its signalling pathway could be a strong means of curing neuroblastomas. Regarding the signalling pathway of MK, receptor-type protein tyrosine phosphatase ζ, anaplastic leukaemia

**Figure 1** Correlation of the plasma MK level with several prognostic factors of neuroblastomas. Single asterisk, $P=0.0005$ or less; double asterisk, $P=0.0007$. The percentage of cases showing more than the cutoff value (500 pg ml$^{-1}$) is shown in parentheses. Statistical analysis is summarised in Table 3.
kinase, and LDL receptor-related protein (LRP) were recently identified as MK receptors (Maeda et al, 1999; Muramatsu et al, 2000; Stoca et al, 2002). Although it has not been elucidated yet whether or not these receptors form complexes for MK signalling, each protein serves as a receptor transducing intracellular signals for midkine. Further investigation of the MK action mechanism should provide insights as to a therapeutic strategy against aggressive neuroblastomas.

A recent report that 13-cis-retinoic acid could be a curative reagent for neuroblastomas (Matthay et al, 1999) prompted us to examine the effect of this reagent on MK production, because MK overproduction should make the prognosis worse if 13-cis-retinoic acid induced MK production. All-trans-retinoic acid as well as 13-cis-retinoic acid induced the intracellular production of MK, but did not enhance the secretion of MK, probably because of premature binding, as described below (manuscript in preparation). The endocytosis of MK is completely dependent on LRP, and initiates nuclear targeting by MK, which is partly needed for the antipoptotic activity of MK (Shibata et al, 2002). In addition, LRP functions as a biosynthesis regulator for MK. Overexpression of MK leads to premature binding and aggregation of MK and LRP in the endoplasmic reticulum during the biosynthesis of both proteins, thus preventing MK overproduction that might cause overgrowth or transformation of cells (manuscript in preparation).

Taken together, the present results suggest that MK production during tumour development needs enhancing mechanisms at least at two steps: mRNA expression and protein secretion.

One of the characteristics of MK expression is that it is frequently and highly expressed in malignant tumours regardless of the tissue type. This phenomenon is reminiscent of mutations in the p53 gene. We previously reported that an elevated serum MK level was detected in more than 80% frequency of human adult carcinomas (Ikematsu et al, 2000). Thus, monitoring of the level of the blood MK is applicable not only to neuroblastomas but also to adult carcinomas. Further assessment of the blood MK level with regard to tumour stages and prognosis of adult malignancy will provide indications for the use of blood MK as a tumour marker for each disease.

ACKNOWLEDGEMENTS

This work was supported by Grants-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan, and Grants-in-Aid for Center of Excellence Research.

REFERENCES

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121 – 1124
Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R (1997) An amplification of N-myc in untreated human prostate carcinoma. British Journal of Cancer (2003) 88(10), 1522 – 1526
Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311: 231 – 235
Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M (1999) A receptor-like protein-tyrosine phosphatase PTP1B.RPTPβ binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTP1B. J Biol Chem 274: 12474 – 12479
Matthay KK, Villalbancan JA, Seeger RC, Straut D, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341: 1165 – 1173
Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T, Kim SU (1993) Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res 35: 530 – 539
Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu T, Kirino T (1997) Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 233: 29 – 32
Muramatsu H, Muramatsu T (1991) Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 177: 652 – 658
Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T (1993) Midkine, a retinoic acid-inducible growth/differentiation factor: immununochromic evidence for the function and distribution. Dev Biol 159: 392 – 402
Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T (2000) LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270: 936 – 941
Muramatsu T (2002) Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 132: 359 – 371
Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847 – 854

Table 3 Statistical analysis as to several prognostic factors

| Prognostic factor | p-value |
|-------------------|---------|
| MYCN amplification + vs – | <0.0001 |
| TrkA expression low vs high | 0.0005 |
| Sporadic vs mass screening | <0.0001 |
| Diploidy vs hyperdiploidy/pentaploidy | 0.007 |
| I year vs 1 year | 0.0299 |

Statistical analysis was performed using the Mann–Whitney U-test.
Blood midkine level in neuroblastomas

S Ikematsu et al

1526

Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Bodeur GM (1995) Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 55: 1792–1797

O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL (1996) The angiogenic factor midkine is expressed in bladder cancer, and over-expression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56: 2515–2518

Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, Michikawa M (1999) Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 73: 2084 – 2092

Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K (2000) Midkine rescues Wilms’ tumor cells from cisplatin-induced apoptosis: regulation of bcl-2 expression by midkine. J Biochem 127: 269 – 277

Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K (2001) Haptotactic migration induced by midkine. Involvement of protein–tyrosine phosphatase, Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 276: 15868 – 15875

Rauvala H, Huttenlocher HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, Kilpelainen I (2000) Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 19: 377 – 387

Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, Muramatsu T (2001) Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 167: 3463 – 3469

Sawada T (1986) Outcome of 25 neuroblastomas revealed by mass screening in Japan. Lancet 1: 377

Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K (2002) Nuclear targeting by the growth factor midkine. Mol Cell Biol 22: 6788 – 6696

Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277: 35990 – 35998

Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T (1997) Midkine, a retinoic acid-inducible heparin-binding cytokine, in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 122: 453 – 458

Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, Kubota S, Muramatsu T (2002) 5’-, 3’-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277: 23800 – 23806

Takei Y, Kadomatsu K, Matsuoh S, Itoh H, Nakazawa K, Kubota S, Muramatsu T (2001) Anti-sense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61: 8486 – 8491

Tomomura M, Kadomatsu K, Matsuobara S, Muramatsu T (1990) A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J Biol Chem 265: 10765 – 10770

Unoki K, Ohba N, Arimura H, Muramatsu H, Muramatsu T (1994) Rescue of photoreceptors from the damaging effects of constant light by midkine, a retinoic acid responsive gene product. Invest Ophthalmo Vis Sci 35: 4063 – 4068

Wada M, Kamata M, Aizu Y, Morita T, Hu J, Oyanagi K (2002) Alteration of midkine expression in the ischemic brain of humans. J Neurol Sci 200: 67 – 73

Wang S, Yoshida Y, Goto M, Morito Y, Tsutsui J, Izumo S, Sato E, Muramatsu T, Osam M (1998) Midkine exists in astrocytes in the early stage of cerebral infarction. Brain Res Dev Brain Res 106: 205 – 209

Yasuahara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGregor PL (1993) Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem Biophys Res Commun 192: 246 – 251

Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, Matsuyma M, Muramatsu T, Kadomatsu K (1999) Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 79: 179 – 184

Yu GSP, Hu J, Nakagawa H (1998) Inhibition of β-amyloid cytotoxicity by midkine. Neurosci Lett 254: 125 – 128